Munro Jonathan, Parham Elahe, DePaoli Damon, Lapointe Nicolas, Akitegetse Cleophace, Fecteau Shirley, Sauvageau Dominic, Di Paolo Thérèse, Côté Daniel C, Parent Martin
Université Laval, CERVO Brain Research Center, Quebec City, Quebec, Canada.
Zilia Inc, Quebec City, Quebec, Canada.
Neurophotonics. 2025 Apr;12(2):025008. doi: 10.1117/1.NPh.12.2.025008. Epub 2025 May 5.
Parkinson's disease (PD) is diagnosed when 50% neurodegeneration has occurred. The retina could provide biomarkers that would allow for earlier diagnosis. Retinal spectroscopy is a technique that could be used to find such biomarkers.
We aimed to find new diagnostic biomarkers for PD following detailed spectral examinations of the retina.
The newly developed Zilia Ocular device was used to perform spectrometric scans of the optic nerve head (ONH) and the retina of four cynomolgus monkeys () before and after the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin used to produce the gold-standard animal model of PD. From the spectrometric data, the blood oximetry was calculated, and the diffuse reflectance spectra (DRS) were analyzed to find variations between the two experimental conditions. Post-mortem analyses were also performed on the retina of the four parkinsonian monkeys and four additional control animals.
The analysis of the DRS indicated a lower slope between the 480- and 525-nm wavelengths in both the ONH and the retina. Post-mortem measurements of the retinal layer thicknesses showed that the outer nuclear layer was significantly thinner in MPTP-intoxicated monkeys, compared with controls. Altogether, these results indicate that MPTP altered the optical properties of the ONH and the retina and show that these variations might be explained by MPTP-induced structural changes in the eye fundus, as observed post-mortem.
Overall, our results indicate that spectroscopy could be used as a noninvasive method to detect changes in the retina that occur in PD and that such changes could represent retinal biomarkers for improved diagnosis.
当发生50%的神经退行性变时,帕金森病(PD)得以确诊。视网膜能够提供有助于早期诊断的生物标志物。视网膜光谱学是一种可用于寻找此类生物标志物的技术。
我们旨在通过对视网膜进行详细的光谱检查来寻找PD的新诊断生物标志物。
使用新开发的Zilia Ocular设备,在给4只食蟹猴注射1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP,一种用于建立PD金标准动物模型的神经毒素)之前和之后,对其视神经乳头(ONH)和视网膜进行光谱扫描。根据光谱数据计算血氧饱和度,并分析漫反射光谱(DRS)以找出两种实验条件之间的差异。还对4只患帕金森病的猴子和另外4只对照动物的视网膜进行了死后分析。
DRS分析表明,ONH和视网膜在480至525纳米波长之间的斜率较低。视网膜层厚度的死后测量结果显示,与对照组相比,MPTP中毒猴子的外核层明显更薄。总体而言,这些结果表明MPTP改变了ONH和视网膜的光学特性,并表明这些变化可能是由MPTP引起的眼底结构变化所解释的,这在死后观察中得到了证实。
总体而言,我们的结果表明光谱学可作为一种非侵入性方法来检测PD患者视网膜中发生的变化,并且这些变化可能代表用于改善诊断的视网膜生物标志物。